Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Targeting Inflammation Emerges as a Strategy for Treating Cancer August 19, 2022 Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 WHO’s plans to create a ‘cervical cancer-free future’ April 19, 2021 Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... July 11, 2022 Load more HOT NEWS Many Older Adults Screened Unnecessarily for Common Cancers Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and... FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal...
